#United States #Los Angeles #UCB #AES 2024 #Epilepsy Research

UCB Showcases Innovative Epilepsy Research at the 2024 AES Annual Meeting in Los Angeles

UCB recently announced its participation in the American Epilepsy Society (AES) Annual Meeting, taking place from December 6 to 10, 2024, in Los Angeles, California. At this prestigious event, UCB will present 32 scientific abstracts that underscore its ongoing commitment to enhancing the quality of life for individuals living with epilepsy.

The research presented focuses on various drugs within UCB's portfolio, particularly FINTEPLA (fenfluramine), which is used in treating seizures associated with complex conditions such as Dravet syndrome and Lennox-Gastaut syndrome. Other notable treatments include BRIVIACT (brivaracetam) and VIMPAT (lacosamide), specifically addressing focal-onset seizures. The meeting will also highlight an investigational treatment known as Staccato® alprazolam designed for acute seizure management.

Exploring the Data

The abstracts encompass not only clinical trial results but also real-world evidence showcasing how these treatments perform outside of controlled environments. For instance, data from a national pharmacy database will detail the real-world usage of fenfluramine in patients with Dravet syndrome, providing insights into its efficacy and safety profiles.

In another study, researchers will discuss the impact of vagus nerve stimulation alongside traditional treatments in managing Lennox-Gastaut syndrome. These findings will contribute to a more nuanced understanding of how these combinatory approaches affect patient outcomes and quality of life.

UCB's efforts extend beyond pharmacological interventions. Research will also delve into the everyday life challenges faced by those with epilepsy, especially concerning sleep quality. One study focuses on the relationship between sleep disturbances and epilepsy, specifically using home sleep EEG assessments. Notably, research highlights the alarming link between sleep apnea and increased mortality rates in pediatric populations suffering from uncontrolled epilepsy.

Quality of Life Assessments

Another significant aspect of UCB’s presentation relates to quality of life surveys, where researchers evaluated the disruptive influences of developmental and epileptic encephalopathies on both patients and their families. These insights will provide invaluable data to fostering a deeper understanding of how prolonged seizures affect not just individuals but also their caregivers and loved ones.

As part of its commitment to serve female patients, UCB will reveal findings from a social listening analysis that captures experiences and challenges encountered by women living with epilepsy throughout their motherhood journey.

Innovations and Pipeline Developments

UCB also aims to inform researchers and practitioners about advancements within its pipeline programs, including investigations surrounding Staccato® alprazolam, a promising inhalation treatment for acute seizure episodes. Presentations will further explore molecular, cellular, and genetic factors related to epilepsy, providing a comprehensive view of potential future therapies and innovations.

Dr. Dimitrios Bourikas, UCB's Global Medical Head of Epilepsy, expressed excitement regarding the opportunity to share groundbreaking research and to collaborate with experts in the field. He emphasized the importance of collective efforts in addressing unmet needs that profoundly affect the communities impacted by epilepsy.

Conclusion

UCB’s contributions to the AES Annual Meeting exemplify the company’s dedication to advancing research in epilepsy treatment. By leveraging clinical data and real-world insights, UCB strives to enhance outcomes for individuals grappling with epilepsy, thus furthering its mission of creating a future with fewer seizures and improved quality of life for those affected. The gathering will serve as an essential platform for discussing promising advancements in epilepsy management and care.